At a glance

ClinicalIndex Comparison Record

Phase 3Completed· 385 enrolled

Drug / intervention

Ga-68 labeled PSMA-11 PETdrug

Likely dose

Not stated in record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02918357

NCT02918357Phase 3Completed

Compare CT.gov

Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence

University of California, San Francisco·interventional·Posted Sep 28, 2016·Updated Dec 2, 2019

In Brief

A Phase 3 clinical trial evaluating Ga-68 labeled PSMA-11 PET for Prostate Cancer. Completed, enrolled 385 participants across 1 site.

Detailed Summary

The investigators are imaging patients with prostate cancer using a new PET imaging agent (Ga-68-PSMA-11) in order to evaluate it's ability to detection prostate cancer in patients with biochemical recurrence after prostatectomy and radiation therapy.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsProstate Cancer

CountriesUnited States

Collaborators--

Timeline

Phase 3CompletedFinished

2017201820192020202120222023202420252026

Enrollment StartSep 2016

First PostedSep 2016

Primary CompletionSep 2017

TodayJul 2026

First PostedSep 28, 2016

Enrollment StartSep 15, 2016

Primary CompletionSep 21, 2017

TodayJul 2, 2026

Enrollment to primary: 1.0 yearsPosted 9.8 years ago

Interventions

Ga-68 labeled PSMA-11 PETdrug

Patients will be imaged using Ga-68 labeled PSMA-11 PET to determine if the presence of metastatic disease. Prostate Specific Membrane Antigen (PSMA) is a protein expressed on prostate cancer cells that can be imaged using small molecules that target this protocol.